Health
First-in-human study with novel antisense oligonucleotide proves promising – Medical Xpress
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a has shown beneficial effects in animal models, including improved vascularization after myocardial infarcti…
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a has shown beneficial effects in animal models, including improved vascularization after myocardial infarction, and accelerated wound healing, according to the peer-reviewed journal Nucleic Acid Therapeutics.
“Based on documented, promising therapeutic potential, locked nucleic acid (LNA)-based anti-miR-92a was further developed and tested in a f…
-
General23 hours agoCoomalie council dismissed by NT government after investigation finds ‘serious deficiencies’
-
Noosa News22 hours agoHuge suburban crowd cheers for luxury house sale at sausage sizzle auction
-
Noosa News23 hours agoTrump’s trade war puts Australian beef centre stage in Shanghai
-
General24 hours agoGrain growers face costly nightmare of ‘clumped’ fertiliser